$ITOS
iTeos Therapeutics, Inc. Stock $itos

$itos Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000156459021015146 Filed on March 24, 2021

Income Statement

Concept	2019 Q4	2019
Revenue		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$8.840M
YoY Change		105.1%
% of Gross Profit
Research & Development		$19.21M
YoY Change		11.76%
% of Gross Profit
Depreciation & Amortization	$460.0K	$610.0K
YoY Change		19.61%
% of Gross Profit
Operating Expenses		$28.05M
YoY Change		30.46%
Operating Profit		-$28.05M
YoY Change
Interest Expense		$0.00
YoY Change		-100.0%
% of Operating Profit
Other Income/Expense, Net		$5.710M
YoY Change		62.22%
Pretax Income		-$22.34M
YoY Change		23.74%
Income Tax		-$119.0K
% Of Pretax Income
Net Earnings		-$22.45M
YoY Change		24.33%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share		-$674.2K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2019	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments		$19.90M
YoY Change		-9.55%
Cash & Equivalents	$19.87M		$22.05M
Short-Term Investments
Other Short-Term Assets		$900.0K
YoY Change		80.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$26.08M	$26.10M
YoY Change		10.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.336M	$1.300M
YoY Change		8.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$293.0K	$400.0K
YoY Change		100.0%
Total Long-Term Assets	$4.668M	$4.600M
YoY Change		24.32%
TOTAL ASSETS
Total Short-Term Assets	$26.08M	$26.10M
Total Long-Term Assets	$4.668M	$4.600M
Total Assets	$30.74M	$30.70M
YoY Change		12.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.174M	$1.200M
YoY Change		-14.29%
Accrued Expenses	$4.262M	$4.300M
YoY Change		115.0%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.20M	$13.20M
YoY Change		164.0%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities	$482.0K	$1.900M
YoY Change		-73.97%
Total Long-Term Liabilities	$482.0K	$1.900M
YoY Change		-73.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.20M	$13.20M
Total Long-Term Liabilities	$482.0K	$1.900M
Total Liabilities	$15.08M	$15.10M
YoY Change		22.76%
SHAREHOLDERS EQUITY
Retained Earnings	-$35.87M
YoY Change
Common Stock	$1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$36.09M	$15.70M	-$10.68M
YoY Change
Total Liabilities & Shareholders Equity	$30.74M	$30.70M
YoY Change		12.04%

Cashflow Statement

Concept	2019 Q4	2019
OPERATING ACTIVITIES
Net Income		-$22.45M
YoY Change		24.33%
Depreciation, Depletion And Amortization	$460.0K	$610.0K
YoY Change		19.61%
Cash From Operating Activities	-$18.33M	-$23.15M
YoY Change		21.18%
INVESTING ACTIVITIES
Capital Expenditures	-$190.0K	$721.0K
YoY Change		-413.48%
Acquisitions
YoY Change
Other Investing Activities	-$120.0K	-$210.0K
YoY Change		200.0%
Cash From Investing Activities	-$310.0K	-$926.0K
YoY Change		208.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$102.0K
YoY Change		-99.57%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	22.54M	22.54M
YoY Change		-4.13%
NET CHANGE
Cash From Operating Activities	-18.33M	-23.15M
Cash From Investing Activities	-310.0K	-926.0K
Cash From Financing Activities	22.54M	22.54M
Net Change In Cash	3.900M	-2.064M
YoY Change		-150.22%
FREE CASH FLOW
Cash From Operating Activities	-$18.33M	-$23.15M
Capital Expenditures	-$190.0K	$721.0K
Free Cash Flow	-$18.14M	-$23.87M
YoY Change		26.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	879000
CY2020Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	4486000
CY2019Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	2360000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	339544000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	26076000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1352000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1336000
CY2020Q4	itos	Research And Development Tax Credit Receivable Non Current ResearchAndDevelopmentTaxCreditReceivableNonCurrent	3286000
CY2019Q4	itos	Research And Development Tax Credit Receivable Non Current ResearchAndDevelopmentTaxCreditReceivableNonCurrent	2917000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19868000
CY2020Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	133000
CY2019Q4	itos	Preferred Stock Tranche Rights Liability PreferredStockTrancheRightsLiability	5400000
CY2019Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	5196000
CY2020Q4	itos	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	192000
CY2019Q4	itos	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	133000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2893000
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2020	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020	dei	Entity File Number EntityFileNumber	001-39401
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-3365066
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	139 Main Street
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
CY2020	dei	City Area Code CityAreaCode	339
CY2020	dei	Local Phone Number LocalPhoneNumber	217 0161
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	35098999
CY2021Q1	dei	Entity Public Float EntityPublicFloat	697600000
CY2020	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value per share
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	336326000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	128000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	122000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	248000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	293000
CY2020Q4	us-gaap	Assets Assets	344558000
CY2019Q4	us-gaap	Assets Assets	30744000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3026000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1174000
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	7486000
CY2019Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	4262000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15340000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8837000
CY2020	us-gaap	Operating Expenses OperatingExpenses	45240000
CY2019	us-gaap	Operating Expenses OperatingExpenses	28048000
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14998000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13196000
CY2020Q4	itos	Grants Repayable GrantsRepayable	5883000
CY2019Q4	itos	Grants Repayable GrantsRepayable	1397000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	35000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	480000
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	482000
CY2020Q4	us-gaap	Liabilities Liabilities	21361000
CY2019Q4	us-gaap	Liabilities Liabilities	15075000
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	51757000
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020	itos	Research And Development Tax Credits ResearchAndDevelopmentTaxCredits	286000
CY2020	itos	Fair Value Adjustment For Preferred Stock Tranche Rights And Anti Dilution Warrant Liabilities FairValueAdjustmentForPreferredStockTrancheRightsAndAntiDilutionWarrantLiabilities	1265000
CY2019	itos	Fair Value Adjustment For Preferred Stock Tranche Rights And Anti Dilution Warrant Liabilities FairValueAdjustmentForPreferredStockTrancheRightsAndAntiDilutionWarrantLiabilities	1019000
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	396443000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	617000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-224000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-73898000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-35865000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	323197000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-36088000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	344558000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30744000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35044758
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	256548
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35044758
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	256548
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29900000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19211000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-45240000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-28048000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-48000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-38090000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22335000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	57000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-119000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-38033000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-22454000
CY2020	us-gaap	Dividends Preferred Stock DividendsPreferredStock	249000
CY2019	us-gaap	Dividends Preferred Stock DividendsPreferredStock	427000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-43402000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26535000
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.88
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-130.85
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15080266
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	202793
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	841000
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-213000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37192000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22667000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-10678000
CY2019	itos	Temporary Equity Accretion To Redemption Value Increase Decrease TemporaryEquityAccretionToRedemptionValueIncreaseDecrease	3654000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	102000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	809000
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-213000
CY2020	itos	Settlement Of Preferred Stock Tranche Right SettlementOfPreferredStockTrancheRight	4135000
CY2020	itos	Temporary Equity Accretion To Redemption Value Increase Decrease TemporaryEquityAccretionToRedemptionValueIncreaseDecrease	5120000
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	181903000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	210612000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	655000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4292000
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	841000
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	19100000
CY2020	us-gaap	Profit Loss ProfitLoss	-38033000
CY2019	us-gaap	Profit Loss ProfitLoss	-22454000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	535000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	611000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	4292000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	809000
CY2020	itos	Deferred Rent Adjustments DeferredRentAdjustments	35000
CY2019	itos	Deferred Rent Adjustments DeferredRentAdjustments	10000
CY2020	itos	Increase Decrease In Grants Receivable IncreaseDecreaseInGrantsReceivable	5175000
CY2019	itos	Increase Decrease In Grants Receivable IncreaseDecreaseInGrantsReceivable	-4136000
CY2020	itos	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	142000
CY2019	itos	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	718000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1927000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	365000
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	12000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1677000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-155000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2759000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2325000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1788000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1979000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25176000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23145000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	356000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	721000
CY2020	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	21000
CY2019	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	205000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-377000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-926000
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	213660000
CY2020	itos	Payments For Initial Public Offering Costs PaymentsForInitialPublicOfferingCosts	3048000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	655000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	102000
CY2020	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	4046000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19990000
CY2019	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	65000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	340339000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	22539000
CY2020	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	1678000
CY2019	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-532000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	316464000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2064000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22054000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	336454000
CY2020	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	181903000
CY2020	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	5120000
CY2019	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	3654000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	63000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	108000
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	23000
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Concentration of credit risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020 and 2019, the Company’s cash and cash equivalents consisted primarily of cash balances held in U.S. dollars in money market funds and money market accounts and euro in accounts with European banks in excess of publicly insured limits. The Company does not believe it is subject to unusual credit risk associated with commercial banking relationships. </p>
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Use of estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses, as well as the related disclosures of contingent assets and liabilities. Estimates are used to determine the fair value of the preferred stock tranche rights liability and anti-dilution warrants liability, the fair value of profit certificates, common stock and stock-based awards and other issuances, accruals for research and development costs, useful lives of long-lived assets, probability of repayment for grants repayable, and uncertain tax positions. Actual results could differ materially from the Company’s estimates.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered the impact of COVID-19 on estimates within its financial statements and there may be changes to those estimates in future periods. As of the date of issuance of these consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of the pandemic and is not aware of any specific related event or circumstance that would require it to update its estimates.</p>
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	30000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	229000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	140000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7486000
CY2019	itos	Proceeds Received From Grants ProceedsReceivedFromGrants	1418000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4262000
CY2020	us-gaap	Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred	1300000
CY2020Q4	us-gaap	Deferred Income Noncurrent DeferredIncomeNoncurrent	5883000
CY2019Q4	us-gaap	Deferred Income Noncurrent DeferredIncomeNoncurrent	1397000
CY2020	itos	Proceeds Received From Grants ProceedsReceivedFromGrants	17053000
CY2020Q3	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Each share of common stock entitles the holders to one vote on all matters submitted to a vote of the Company’s stockholders.
CY2020Q4	itos	Stock Options Issued And Outstanding StockOptionsIssuedAndOutstanding	4552396
CY2020Q4	itos	Accrued Personnel Costs Current AccruedPersonnelCostsCurrent	3208000
CY2019Q4	itos	Accrued Personnel Costs Current AccruedPersonnelCostsCurrent	1409000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	37000
CY2019Q4	itos	Stock Options Issued And Outstanding StockOptionsIssuedAndOutstanding	1387003
CY2020Q4	itos	Shares Available For Issuance Under Stock Option Plan SharesAvailableForIssuanceUnderStockOptionPlan	3039222
CY2019Q4	itos	Shares Available For Issuance Under Stock Option Plan SharesAvailableForIssuanceUnderStockOptionPlan	251606
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	7591618
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10261923
CY2020Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2019Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2020	itos	Research And Development Tax Credits Percentage ResearchAndDevelopmentTaxCreditsPercentage	0.135
CY2019	itos	Research And Development Tax Credits Percentage ResearchAndDevelopmentTaxCreditsPercentage	0.135
CY2020	us-gaap	Property Plant And Equipment Estimated Useful Lives PropertyPlantAndEquipmentEstimatedUsefulLives	Shorter of useful life or term of lease
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2020Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	314636000
CY2020Q4	us-gaap	Financial Instruments Owned At Fair Value FinancialInstrumentsOwnedAtFairValue	314636000
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	1265000
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	618000
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1265000
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1019000
CY2020Q4	us-gaap	Derivative Assets DerivativeAssets	0
CY2019Q4	us-gaap	Derivative Assets DerivativeAssets	0
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4014000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3417000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2662000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2081000
CY2020Q4	itos	Accrued Clinical Trial Costs Current AccruedClinicalTrialCostsCurrent	4012000
CY2019Q4	itos	Accrued Clinical Trial Costs Current AccruedClinicalTrialCostsCurrent	2683000
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.25
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P36M
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1387003
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3504715
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	102863
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	236459
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4552396
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4552396
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	861388
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.62
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.43
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.18
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.77
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.13
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	9.13
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.93
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y9M18D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M12D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y2M12D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	112412000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	112412000
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	24889000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4292000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	809000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.75
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.49
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3100000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	800000
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	700000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0250
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0036
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0135
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.93
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.90
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.02
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2019	itos	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Common Stock ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStock	2.38
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-31184000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-689000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-6906000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-21646000
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.002
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.005
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	itos	Effective Income Tax Rate Reconciliation State Income Taxes Percent EffectiveIncomeTaxRateReconciliationStateIncomeTaxesPercent	0.048
CY2019	itos	Effective Income Tax Rate Reconciliation State Income Taxes Percent EffectiveIncomeTaxRateReconciliationStateIncomeTaxesPercent	0.001
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.008
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.083
CY2020	itos	Effective Income Tax Rate Reconciliation Relating To Non Taxable Income And Non Deductible Expense EffectiveIncomeTaxRateReconciliationRelatingToNonTaxableIncomeAndNonDeductibleExpense	0.034
CY2019	itos	Effective Income Tax Rate Reconciliation Relating To Non Taxable Income And Non Deductible Expense EffectiveIncomeTaxRateReconciliationRelatingToNonTaxableIncomeAndNonDeductibleExpense	0.076
CY2020	itos	Effective Income Tax Rate Reconciliation Local Income Taxes Percent EffectiveIncomeTaxRateReconciliationLocalIncomeTaxesPercent	-0.086
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.009
CY2020	itos	Effective Income Tax Rate Reconciliation Change In Valuation Allowance Percent EffectiveIncomeTaxRateReconciliationChangeInValuationAllowancePercent	-0.221
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	29000000
CY2020	itos	Date Expiring Net Operating Loss Carry Forwards Available To Offset Future Income Tax Liabilities DateExpiringNetOperatingLossCarryForwardsAvailableToOffsetFutureIncomeTaxLiabilities	2040
CY2020	itos	Date Expiring De Minimis Federal Future Tax Liabilities DateExpiringDeMinimisFederalFutureTaxLiabilities	2040
CY2020	itos	Date Expiring State Tax Credit Available To Reduce Future Tax Liabilities DateExpiringStateTaxCreditAvailableToReduceFutureTaxLiabilities	2025
CY2020Q1	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	0.1
CY2019	itos	Effective Income Tax Rate Reconciliation Change In Valuation Allowance Percent EffectiveIncomeTaxRateReconciliationChangeInValuationAllowancePercent	-0.375
CY2020	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	-60000
CY2019	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	116000
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	3000
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	3000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	25206000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	14176000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	6219000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7397000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	758000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	313000
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	110000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	32496000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21683000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	32029000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21673000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	467000
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	10000
CY2020Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	445000
CY2020Q4	itos	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	22000
CY2019Q4	itos	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	10000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	467000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	10000
CY2020	itos	Net Increase Decrease In Deferred Tax Assets Valuation Allowance NetIncreaseDecreaseInDeferredTaxAssetsValuationAllowance	10300000
CY2020Q4	itos	Net Operating Loss Carry Forwards Available To Offset Future Income Tax Liabilities NetOperatingLossCarryForwardsAvailableToOffsetFutureIncomeTaxLiabilities	29200000
CY2020	itos	Net Operating Loss Carry Forwards Deductible At Maximum Rate Of Corporations Taxable Income NetOperatingLossCarryForwardsDeductibleAtMaximumRateOfCorporationsTaxableIncome	0.80
CY2017	itos	Net Operating Loss Carry Forwards Deductible At Maximum Rate Of Corporations Taxable Income NetOperatingLossCarryForwardsDeductibleAtMaximumRateOfCorporationsTaxableIncome	1.00
CY2020Q4	itos	Net Operating Loss Available To Offset Rate For Taxable Income Limitation Under Tcja NetOperatingLossAvailableToOffsetRateForTaxableIncomeLimitationUnderTCJA	0.80
CY2020	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	0.1
CY2020Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P4Y
CY2020	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	600000
CY2019	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	500000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	667000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	504000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	385000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	349000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	318000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1369000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3592000
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.05
CY2020	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	167000
CY2019	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	141000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4552396
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10010317

Files In Submission

Name	View Source	Status
0001564590-21-015146-index-headers.html	Edgar Link	pending
0001564590-21-015146-index.html	Edgar Link	pending
0001564590-21-015146.txt	Edgar Link	pending
0001564590-21-015146-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gdbhyij0addj000001.jpg	Edgar Link	pending
gdbhyij0addj000002.jpg	Edgar Link	pending
gdbhyij0addj000003.jpg	Edgar Link	pending
gdbhyij0addj000004.jpg	Edgar Link	pending
gdbhyij0addj000005.jpg	Edgar Link	pending
gdbhyij0addj000006.jpg	Edgar Link	pending
gdbhyij0addj000007.jpg	Edgar Link	pending
gdbhyij0addj000008.jpg	Edgar Link	pending
gdbhyij0addj000009.jpg	Edgar Link	pending
gdbhyij0addj000010.jpg	Edgar Link	pending
gdbhyij0addj000011.jpg	Edgar Link	pending
gdbhyij0addj000012.jpg	Edgar Link	pending
gdbhyij0addj000013.jpg	Edgar Link	pending
gdbhyij0addj000014.jpg	Edgar Link	pending
gdbhyij0addj000015.jpg	Edgar Link	pending
gdbhyij0addj000016.jpg	Edgar Link	pending
gdbhyij0addj000017.jpg	Edgar Link	pending
gdbhyij0addj000018.jpg	Edgar Link	pending
gdbhyij0addj000019.jpg	Edgar Link	pending
gdbhyij0addj000020.jpg	Edgar Link	pending
gdbhyij0addj000021.jpg	Edgar Link	pending
gdbhyij0addj000022.jpg	Edgar Link	pending
gdbhyij0addj000023.jpg	Edgar Link	pending
gdbhyij0addj000024.jpg	Edgar Link	pending
gdbhyij0addj000025.jpg	Edgar Link	pending
gdbhyij0addj000026.jpg	Edgar Link	pending
gdbhyij0addj000027.jpg	Edgar Link	pending
gdbhyij0addj000028.jpg	Edgar Link	pending
gdbhyij0addj000029.jpg	Edgar Link	pending
gdbhyij0addj000030.jpg	Edgar Link	pending
gdbhyij0addj000031.jpg	Edgar Link	pending
gdbhyij0addj000032.jpg	Edgar Link	pending
itos-10k_20201231.htm	Edgar Link	pending
itos-20201231.xml	Edgar Link	completed
itos-20201231.xsd	Edgar Link	pending
itos-20201231_cal.xml	Edgar Link	unprocessable
itos-20201231_def.xml	Edgar Link	unprocessable
itos-20201231_lab.xml	Edgar Link	unprocessable
itos-20201231_pre.xml	Edgar Link	unprocessable
itos-ex211_570.htm	Edgar Link	pending
itos-ex231_515.htm	Edgar Link	pending
itos-ex311_9.htm	Edgar Link	pending
itos-ex312_8.htm	Edgar Link	pending
itos-ex321_6.htm	Edgar Link	pending
itos-ex322_7.htm	Edgar Link	pending
itos-ex43_516.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ITOS
iTeos Therapeutics, Inc. Stock $itos

2019 Q4 Form 10-K Financial Statement

#000156459021015146 Filed on March 24, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ITOS iTeos Therapeutics, Inc. Stock $itos

2019 Q4 Form 10-K Financial Statement

#000156459021015146 Filed on March 24, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ITOS
iTeos Therapeutics, Inc. Stock $itos